Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone510-970-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$84.45 million
Profitability
Miscellaneous
Employees302
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions
What is Sangamo Therapeutics' stock symbol?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics Inc (NASDAQ:SGMO) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The biopharmaceutical company earned $17.55 million during the quarter, compared to analysts' expectations of $13.58 million. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. Sangamo Therapeutics's quarterly revenue was down 18.1% on a year-over-year basis. During the same period last year, the company posted ($0.17) earnings per share. View Sangamo Therapeutics' Earnings History.
When is Sangamo Therapeutics' next earnings date?
What price target have analysts set for SGMO?
3 equities research analysts have issued 12-month price objectives for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $13.3333 in the next year. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.
What is the consensus analysts' recommendation for Sangamo Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sangamo Therapeutics.
Has Sangamo Therapeutics been receiving favorable news coverage?
News headlines about SGMO stock have trended positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sangamo Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Sangamo Therapeutics.
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD) and Regenxbio (RGNX).
What other stocks do shareholders of Sangamo Therapeutics own?
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the folowing people:
- Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
- Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
- Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
- Dr. Edward Rebar, Sr. VP & CTO
- Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations
Who are Sangamo Therapeutics' major shareholders?
Sangamo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.15%), Vanguard Group Inc. (7.18%), Wasatch Advisors Inc. (5.72%), Northern Trust Corp (1.19%), Alexandria Capital LLC (0.79%) and Wells Fargo & Company MN (0.71%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.
Which major investors are selling Sangamo Therapeutics stock?
SGMO stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Renaissance Technologies LLC, Bank of America Corp DE, Allianz Asset Management GmbH, Morgan Stanley, Rhenman & Partners Asset Management AB, WS Management Lllp and BNP Paribas Arbitrage SA. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Edward R Conner and Kathy Yi. View Insider Buying and Selling for Sangamo Therapeutics.
Which major investors are buying Sangamo Therapeutics stock?
SGMO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Vanguard Group Inc., Candriam Luxembourg S.C.A., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Wells Fargo & Company MN and Wasatch Advisors Inc.. View Insider Buying and Selling for Sangamo Therapeutics.
How do I buy shares of Sangamo Therapeutics?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sangamo Therapeutics' stock price today?
One share of SGMO stock can currently be purchased for approximately $11.02.
How big of a company is Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $1.27 billion and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.
What is Sangamo Therapeutics' official website?
How can I contact Sangamo Therapeutics?
Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]
MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
